Phaseline

Companies › Kiromic BioPharma

Kiromic BioPharma: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
KB-GDT-01
Allogeneic gamma delta T-cell suspension product
–Phase 1Carcinoma, Non-Small-Cell Lung Cancer–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06069570KB-GDT-01Phase 1Carcinoma, Non-Small-Cell Lung CancerOncologyOct 2025

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.